CFTR and aspergillosis: Structure-based hit optimization and pharmaceutical formulations for localized lung delivery will pave the way for the translational development of potential drugs in the perspective of a combination therapy with HEMT to integrate CFTR correction and potentiation with immune and microbial modulating activities, at least in the context of aspergillosis.